Skip Navigation

Europace 2003 5(s1):S49-S54; doi:10.1016/j.eupc.2004.07.007
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Padeletti, L.
Right arrow Articles by Gensini, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Padeletti, L.
Right arrow Articles by Gensini, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Atrial fibrillation and cardiac resynchronization therapy: the MASCOT study

Luigi Padelettia,*, Nicola Musillia, Maria Cristina Porciania, Andrea Colellaa, Luigi Di Biaseb, Giuseppe Ricciardia, Paolo Pieragnolia, Antonio Micheluccia and GianFranco Gensinia

aInstitute of Internal Medicine and Cardiology, University of Florence Florence, Italy; bCardiovascular Institute, University of Bari Bari, Italy

Atrial fibrillation (AF) and congestive heart failure (CHF) share several characteristics and often coexist in the same patient. Both are responsible for significant morbidity and mortality, are increasing in prevalence, and are major sources of health expenditure. The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy (MASCOT) study is a European, single-blind, prospective, controlled, multicentre, randomized clinical trial designed to examine whether adding the AF SuppressionTM Algorithm to cardiac resynchronization therapy (CRT) improves the prognosis of patients with CHF. The patients will be randomly assigned to a CRT-only group, with the AF SuppressionTM algorithm programmed OFF (control group), versus a CRT + AF SuppressionTM group, with the algorithm programmed ON (treatment group). The primary study endpoint is development of permanent AF, and secondary endpoints are safety of the AF SuppressionTM algorithm, and evolution of multiple clinical variables over 24 months of follow-up. CRT combined with a refined atrial tachyarrhythmia prevention pacing algorithm may represent a major advance in the management of AF and CHF by electrical stimulation.

Key Words: atrial fibrillation, cardiac resynchronization therapy, atrial pacing, overdrive pacing

*Corresponding author. Tel.: +39 055 4277634; fax: +39 055 4378368. E-mail address: elettrofisiologia{at}dac.unifi.it (L. Padeletti).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.